STAT+: AstraZeneca’s GLP-1 pill shows promise in obesity, diabetes trials

AstraZeneca's GLP-1 pill demonstrated promise in mid-stage obesity and diabetes studies, achieving a 10.5% weight loss. While these results are positive, it remains too early to determine how the medication compares to other available oral treatments. The trials focused on the drug's efficacy in treating obesity and diabetes, showing potential for weight reduction. Further data is needed to establish its competitive standing against other oral GLP-1 therapies currently being developed or marketed.